Compare AbCellera Biologics Inc (ABCL) vs Walt Disney Co (DIS) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Disney (DIS) trades at $97.41, down 2.06% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $1.88. Revenue growth has accelerated from $82.7B in 2022 to $94.4B in 2025, while net income surged to $12.4B. Analyst consensus remains strongly bullish with a $131.89 price target, representing 35% upside potential from current levels.

Disney presents a compelling investment case with improving profitability and strong cash flow generation, though regulatory challenges and recent box office disappointments pose near-term risks. The stock's current valuation at 15.59x P/E appears attractive relative to growth prospects, while technical indicators suggest potential support near $94-96 levels.